By Giovanni Luca Beretta, Franco Zunino (auth.), Karsten Krohn (eds.)
see desk of contents
Read or Download Anthracycline Chemistry and Biology II: Mode of Action, Clinical Aspects and New Drugs PDF
Best chemistry books
Pergamon Texts in Inorganic Chemistry, quantity five: The Chemistry of Fluorine includes a sequence of stories at the actual and chemical houses of fluorine compounds. This ebook discusses the final houses of fluorine and fluorides; hydrogen fluoride solvent process; ionization in halogen fluorides; fluorides of major crew components; and chemical reactivity of upper fluorides of d- and f-transition parts.
- Chemie didaktik. Diagnose und Korrektur von Schulervorstellungen
- NIOSH Pocket Guide to Chemical Hazards Sept. 2005
- Advances in Carbohydrate Chemistry, Vol. 6
- Advances in Chemical Physics (Volume 139)
- Handbook of Heterogeneous Catalysis
- Carbohydrate Chemistry
Additional info for Anthracycline Chemistry and Biology II: Mode of Action, Clinical Aspects and New Drugs
Panel A). [Concentration × potency] factors were calculated by assuming that DOXOL was 40-times more potent than DOX toward ATP-dependent Ca2+ handling proteins; based on data in [26, 27, 29] Anthracycline Cardiotoxicity 29 should be interpreted with due caution. In human myocardial samples the fractional conversion of DOX and EPI to DOXOL or EPIOL usually averaged ≤1% [26, 27, 34, 35]: this would be too low for DOXOL or EPIOL to play a major role in cellular damage, even if one considered that the metabolites were ∼30–40 times more reactive than DOX or EPI.
There have been variable levels of interest in examining such differences; here, we will brieﬂy review some lessons from IDA or EPI. Idarubicin (administered by the canonical iv route) was shown to decrease the left ventricular ejection fraction (LVEF) in anthracycline-naïve patients, or to cause CHF in patients with preexisting cardiovascular disease or prior anthracycline treatment . In the light of its very high lipophilicity, IDA was subsequently administered also per os, and the studies that adopted this route showed essentially no cardiotoxicity .
Arcamone F, Animati F, Berettoni M, Bigioni M, Capranico G, Casazza AM, Caserini C, Cipollone A, De Cesare M, Franciotti M, Lombardi P, Madami A, Manzini S, Monteagudo E, Polizzi D, Pratesi G, Righetti SC, Salvatore C, Supino R, Zunino F (1997) J Natl Cancer Inst 89:1217 67. Pratesi G, De Cesare M, Caserini C, Perego P, Dal Bo L, Polizzi D, Supino R, Bigioni M, Manzini S, Iafrate E, Salvatore C, Casazza A, Arcamone F, Zunino F (1998) Clin Cancer Res 4:2833 68. Minotti G, Licata S, Saponiero A, Menna P, Calaﬁore AM, Di Giammarco G, Liberi G, Animati F, Cipollone A, Manzini S, Maggi CA (2000) Chem Res Toxicol 13:1336 69.
Anthracycline Chemistry and Biology II: Mode of Action, Clinical Aspects and New Drugs by Giovanni Luca Beretta, Franco Zunino (auth.), Karsten Krohn (eds.)